These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12838296)

  • 21. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
    Tscherry G; Jacky E; Jost LM; Stahel RA
    Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience.
    Richardson NH; Taza F; Abonour R; Althouse SK; Ashkar R; Abu Zaid M; Hanna NH; Kesler KA; Adra N; Einhorn LH
    Cancer; 2024 Sep; 130(18):3115-3122. PubMed ID: 38768296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
    Bajorin DF; Nichols CR; Schmoll HJ; Kantoff PW; Bokemeyer C; Demetri GD; Einhorn LH; Bosl GJ
    J Clin Oncol; 1995 Jan; 13(1):79-86. PubMed ID: 7799046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
    J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
    Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
    Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
    Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
    Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
    Daugaard G; Skoneczna I; Aass N; De Wit R; De Santis M; Dumez H; Marreaud S; Collette L; Lluch JRG; Bokemeyer C; Schmoll HJ
    Ann Oncol; 2011 May; 22(5):1054-1061. PubMed ID: 21059637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) For advanced testicular cancer].
    Fujii Y; Kihara K; Kamata S; Tsujii T; Ishizaka K; Kageyama Y; Masuda H; Arisawa C; Oshima H; Komatsu F
    Hinyokika Kiyo; 1998 May; 44(5):313-8. PubMed ID: 9656101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
    Bokemeyer C; Schmoll HJ; Harstrick A; Illiger HJ; Metzner B; Räth U; Hohnloser J; Clemm C; Berdel W; Siegert W
    Eur J Cancer; 1993; 29A(16):2225-31. PubMed ID: 8110490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary mediastinal nonseminomatous germ cell tumors: the influence of postchemotherapy pathology on long-term survival after surgery.
    Kesler KA; Rieger KM; Ganjoo KN; Sharma M; Fineberg NS; Einhorn LH; Brown JW
    J Thorac Cardiovasc Surg; 1999 Oct; 118(4):692-700. PubMed ID: 10504636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
    Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
    Rick O; Siegert W; Beyer J
    Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.
    Lewis CR; Fossà SD; Mead G; ten Bokkel Huinink W; Harding MJ; Mill L; Paul J; Jones WG; Rodenburg CJ; Cantwell B
    Ann Oncol; 1991 Mar; 2(3):203-11. PubMed ID: 1710482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors.
    Ganjoo KN; Rieger KM; Kesler KA; Sharma M; Heilman DK; Einhorn LH
    Cancer; 2000 Mar; 88(5):1051-6. PubMed ID: 10699894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment.
    Pentheroudakis G; De Bono JS; Kaye SB; Simpson A; Paul J; Brown I; Pamenter B; Kirk A; Vasey P; Raby N; Kirk D
    BJU Int; 2003 Jul; 92(1):36-42. PubMed ID: 12823380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG).
    Germà-Lluch JR; Garcia del Muro X; Tabernero JM; Sánchez M; Aparicio J; Alba E; Barnadas A
    Ann Oncol; 1999 Mar; 10(3):289-93. PubMed ID: 10355572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.